Extended duration of anticoagulation for cancer-associated thrombosis
Tzu-Fei Wang1, Marc Carrier1* 1Department of Medicine, University of Ottawa at the Ottawa Hospital and The Ottawa...
Most Read
Novel Biomarkers for Thrombosis Risk Prediction in Non–Small-Cell Lung Cancer: Insights from Recent Evidence
Venous thromboembolism (VTE) represents a significant cause of morbidity and mortality in patients with cancer,...
Arterial thrombosis and pediatric cancer- should cancer associated pediatric stroke be studied?
While knowledge of arterial thromboembolism prevalence and risk factors among adult cancer patients is currently...
KRAS-activating mutations: an independent risk factor for VTE?
Colorectal cancer (CRC) is the third most common type of cancer in Europe , after breast and prostate cancer, and...
Developmental hemostasis and its relevance to pediatric thrombosis
The coagulation system of neonates and children evolves with age, as evidenced by marked physiological differences in...
Platelet Cut-Off for Anticoagulant Therapy in Thrombocytopenic Patients with Blood Cancer and Venous Thromboembolism
Venous thromboembolism (VTE) is a recurrent risk factor in cancer patients. In particular, patients with hematologic...
A new section with a focus on COVID-19 is available on the ICTHIC magazine website!
In these unprecedented times, we would like to provide specific information on COVID-19 and the related issues on...
Treatment of VTE in the colorectal cancer patient
In clinical practice, cancer-associated thrombosis (CAT) is a frequent phenomenon among colorectal cancer (CRC)...
Can Thrombophilia Gene Mutations be Predictors of VTE in Ambulatory Cancer Patients Undergoing Chemotherapy?
Thrombophilia refers to a group of conditions where the blood has an elevated tendency to form clots. It can stem from...
Exploring the relationship between hemostasis and cancer in Bergamo
From 13-15 April 2018, the most expert clinicians and basic science researchers in the field of hematology and oncology...